UTHR vs. NBIX
UTHR (United Therapeutics Corporation) and NBIX (Neurocrine Biosciences, Inc.) are both stocks. Both are in the Healthcare sector — UTHR in Biotechnology, NBIX in Drug Manufacturers - Specialty & Generic. Over the past 10 years, UTHR returned 16.80%/yr vs 12.34%/yr for NBIX. At a 0.34 correlation, their price movements are largely independent.
Performance
UTHR vs. NBIX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, UTHR achieves a 12.85% return, which is significantly lower than NBIX's 15.55% return. Over the past 10 years, UTHR has outperformed NBIX with an annualized return of 16.80%, while NBIX has yielded a comparatively lower 12.34% annualized return.
UTHR
- 1D
- 0.40%
- 1M
- -7.86%
- YTD
- 12.85%
- 6M
- 12.38%
- 1Y
- 71.99%
- 3Y*
- 35.66%
- 5Y*
- 25.60%
- 10Y*
- 16.80%
NBIX
- 1D
- -2.07%
- 1M
- 11.47%
- YTD
- 15.55%
- 6M
- 5.38%
- 1Y
- 31.51%
- 3Y*
- 19.76%
- 5Y*
- 11.67%
- 10Y*
- 12.34%
UTHR vs. NBIX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
UTHR United Therapeutics Corporation | 12.85% | 38.09% | 60.46% | -20.93% | 28.70% | 42.35% | 72.33% | -19.12% | -26.39% | 3.15% |
NBIX Neurocrine Biosciences, Inc. | 15.55% | 3.90% | 3.60% | 10.31% | 40.24% | -11.14% | -10.83% | 50.53% | -7.96% | 100.49% |
Correlation
The correlation between UTHR and NBIX is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.32 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.32 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.30 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.33 |
Correlation (All Time) Calculated using the full available price history since Jun 18, 1999 | 0.34 |
Fundamentals
UTHR:
$25.95B
NBIX:
$16.95B
UTHR:
$27.00
NBIX:
$6.53
UTHR:
20.36
NBIX:
25.09
UTHR:
0.67
NBIX:
0.49
UTHR:
8.27
NBIX:
5.41
UTHR:
4.40
NBIX:
4.97
UTHR:
$3.17B
NBIX:
$3.10B
UTHR:
$2.74B
NBIX:
$3.05B
UTHR:
$1.75B
NBIX:
$881.20M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
UTHR vs. NBIX — Risk / Return Rank
UTHR
NBIX
UTHR vs. NBIX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for United Therapeutics Corporation (UTHR) and Neurocrine Biosciences, Inc. (NBIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| UTHR | NBIX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.44 | ||
| Sortino ratioReturn per unit of downside risk | +1.37 | ||
| Omega ratioGain probability vs. loss probability | 1.39 | 1.21 | +0.18 |
| Calmar ratioReturn relative to maximum drawdown | 4.43 | 1.51 | +2.91 |
| Martin ratioReturn relative to average drawdown | 11.34 | 3.33 | +8.01 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| UTHR | NBIX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.45 | 1.02 | +0.44 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.73 | 0.36 | +0.37 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.48 | 0.32 | +0.16 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.38 | 0.14 | +0.24 |
Drawdowns
UTHR vs. NBIX - Drawdown Comparison
The maximum UTHR drawdown since its inception was -93.18%, roughly equal to the maximum NBIX drawdown of -97.21%. Use the drawdown chart below to compare losses from any high point for UTHR and NBIX.
Loading charts...
Drawdown Indicators
| UTHR | NBIX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.18% | -97.21% | +4.03% |
Max Drawdown (1Y)Largest decline over 1 year | -16.35% | -20.90% | +4.55% |
Max Drawdown (3Y)Largest decline over 3 years | -33.00% | -42.89% | +9.89% |
Max Drawdown (5Y)Largest decline over 5 years | -33.00% | -42.89% | +9.89% |
Max Drawdown (10Y)Largest decline over 10 years | -55.56% | -46.39% | -9.17% |
Current DrawdownCurrent decline from peak | -7.86% | -2.07% | -5.79% |
Average DrawdownAverage peak-to-trough decline | -35.31% | -43.84% | +8.53% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.37% | 9.48% | -3.11% |
Volatility
UTHR vs. NBIX - Volatility Comparison
The current volatility for United Therapeutics Corporation (UTHR) is 6.84%, while Neurocrine Biosciences, Inc. (NBIX) has a volatility of 10.24%. This indicates that UTHR experiences smaller price fluctuations and is considered to be less risky than NBIX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| UTHR | NBIX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.84% | 10.24% | -3.40% |
Volatility (6M)Calculated over the trailing 6-month period | 26.00% | 23.68% | +2.32% |
Volatility (1Y)Calculated over the trailing 1-year period | 49.78% | 31.18% | +18.60% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 35.14% | 32.73% | +2.41% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 35.08% | 39.16% | -4.08% |
Dividends
UTHR vs. NBIX - Dividend Comparison
Neither UTHR nor NBIX has paid dividends to shareholders.
Financials
UTHR vs. NBIX - Financials Comparison
This section allows you to compare key financial metrics between United Therapeutics Corporation and Neurocrine Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
UTHR vs. NBIX - Profitability Comparison
UTHR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, United Therapeutics Corporation reported a gross profit of 648.10M and revenue of 781.50M. Therefore, the gross margin over that period was 82.9%.
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a gross profit of 800.70M and revenue of 814.50M. Therefore, the gross margin over that period was 98.3%.
UTHR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, United Therapeutics Corporation reported an operating income of 325.80M and revenue of 781.50M, resulting in an operating margin of 41.7%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported an operating income of 193.40M and revenue of 814.50M, resulting in an operating margin of 23.7%.
UTHR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, United Therapeutics Corporation reported a net income of 274.90M and revenue of 781.50M, resulting in a net margin of 35.2%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a net income of 197.90M and revenue of 814.50M, resulting in a net margin of 24.3%.
Frequently Asked Questions
UTHR and NBIX have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NBIX has higher volatility (10.24%) compared to UTHR (6.84%). In terms of maximum drawdown, UTHR dropped -93.18% vs NBIX's -97.21%.
UTHR currently has the higher Sharpe Ratio (1.45 vs 1.02), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for UTHR and NBIX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer